Xin YuJHubbardVMTangJ.Immuno-oncology drug development goes global. Nat Rev Drug Discov2019;
18: 899–900.
2.
ChatelutELe LouedecFMilanoG.Setting the dose of checkpoint inhibitors: the role of clinical pharmacology. Clin Pharmacokinet2020;
59: 287–296.
3.
ShahNJKellyWJLiuSV, et al.
Product review on the anti-PD-L1 antibody. Hum Vaccin Immunother2018;
14: 269–276.
4.
ZhaoXSuryawanshiSHruskaM, et al.
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumours. Ann Oncol2017;
28: 2002–2008.
5.
LongGVTykodiSSSchneiderJG, et al.
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol2018;
29: 2208–2213.
6.
LalaMLiMSinhaV, et al.
A six-weekly (Q6H) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modelling and simulation. JCO2018;
36: 3062–3062.
7.
NovakovicAMWilkinsJJDaiH, et al.
Changing body weight-based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther2020;
107: 588–596.
8.
GilbarPJChambersCRGilbarEC.Opportunities to significantly reduce expenditure associated with cancer drugs. Future Oncol2017;
13: 1311–1322.
9.
GilbarPJChambersCR.How can we ensure value for money from expenditure on injectable cancer drugs?J Oncol Pharm Pract2018;
24: 473–476.
10.
VaddepallyRKKharelPPandeyR, et al.
Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with level of evidence. Cancers2020;
12: 738.
11.
RennerABurottoMRojasC.Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?J Glob Oncol2020;
5: 1–5.
12.
BachPBContiRMMullerRJ, et al.
Overspending driven by oversized single dose vials of cancer drugs. BMJ2016;
352: i788.
13.
OgungbenroKPatelADuncombeR, et al.
Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modelling and simulation and cost analysis. Clin Pharmacol Ther2018;
103: 582–590.
14.
BayleABesseBAnnereauM, et al.
Switch to anti-programmed cell death protein (anti-PD-1) fixed-dose regimen: what is the economic impact?Eur J Cancer2019;
113: 28–31.
15.
ClarenneJBoulangerCMarechalA, et al.
Economical simulations for the optimal use of anti-programmed cell death-1 in advanced melanoma patients: report of a budget impact analysis. J Oncol Pharm Pract2020;
26: 1216–1219.
16.
HallEZhangJKimEJ, et al.
Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Med2020;
9: 2106–2112.
17.
RatainMJGoldsteinDA.Time is money: optimizing the scheduling of nivolumab. JCO2018;
36: 3074–3076.
18.
GoldsteinDAGordonNDavidescuM, et al.
A pharmacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer. J Nat Cancer Inst2017;
109: djx063.
19.
JangANakashimaLNgT, et al.
A real-world data approach to determine the optimal dosing strategy for pembrolizumab. J Oncol Pharm Pract. Epub ahead of print 15 June 2020. DOI: 10.1177/1078155220929756.
20.
De LemosMLKungCWaigneinS.Efficacy of nivolumab four-weekly dosing schedule based on body weight. J Oncol Pharm Pract2019;
25: 961–963.
21.
HatswellAJPorterJK.Reducing drug wastage in pharmaceuticals dosed by weight of body surface areas by optimizing vial sizes. Appl Health Econ Health Policy2019;
17: 391–397.
22.
GoldsteinDARatainMJSaltzLB.Weight-based dosing of pembrolizumab every 6 weeks in the time of COVID-19. JAMA Oncol. Epub ahead of print 27 May 2020. DOI: 10.1001/jamaoncol.2020.2493.
23.
TopalianSLHodiFSBrahmerJR, et al.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med2012;
366: 2443–2454.
24.
GilbarPJSungJBrownVJ, et al.
Expanding the war on waste: recycling cancer drugs. J Pharm Pract Res2019;
49: 454–459.
25.
GilbarPJChambersCRVandenbroucheJ, et al.
How can the use of closed system transfer devices to facilitate sharing of drug vials be optimised to achieve maximum cost savings?J Oncol Pharm Pract2019;
25: 205–209.
